4D Molecular Therapeutics (FDMT) Registration filing summary

Company overview and business model

• Late-stage biotechnology company developing durable, disease-targeted therapeutics using proprietary adeno-associated virus (AAV) vectors from its Therapeutic Vector Evolution (TVE) platform.

• Focused on clinical-stage product candidates for retinal and pulmonary diseases with high unmet need, including wet age-related macular degeneration, diabetic macular edema, geographic atrophy, and cystic fibrosis.

• Lead candidate 4D-150 targets retinal vascular diseases with a durable, in-office therapy aiming to reduce treatment burden and improve vision outcomes.

• Additional pipeline includes 4D-175 for geographic atrophy and 4D-710 for cystic fibrosis, both leveraging proprietary vectors and showing promising clinical or preclinical results.

Financial performance and metrics

• Reference is made to financial statements and reports incorporated by reference, including the Annual Report on Form 10-K for the year ended December 31, 2025, and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement for each offering.